{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:29:56Z","timestamp":1790872196188,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Intensive chemotherapy is standard for acute myeloid leukemia (AML) but carries high risks of life-threatening complications, particularly in vulnerable patients. We aimed to compare the efficacy and safety of a low-dose chemotherapy (LDC) regimen for induction of AML. A randomized, multicenter, noninferiority trial was conducted in patients with AML aged &amp;lt;18 years. Patients received low-dose cytarabine, mitoxantrone or idarubicin, and granulocyte colony-stimulating factor (G-CSF) or standard-dose chemotherapy (SDC; cytarabine, daunomycin, and etoposide). All patients received postremission consolidation with standard chemotherapy and\/or hematopoietic stem cell transplantation. The primary end point was to compare response rates between treatments. The secondary end points were to compare the outcomes, toxicity, and safety of the LDC and SDC regimens. The 2 treatment arms showed no significant differences in outcomes. Complete remission (CR)\/CR with incomplete count recovery rates after induction were 95.1% and 95.3% in the LDC and SDC arms, respectively. Measurable residual disease &amp;lt;0.1% after induction II was observed in 87.4% and 87.1% of patients in the LDC and SDC arms, respectively. Median time to neutrophil and platelet recovery was significantly shorter among patients receiving the LDC regimen. Patients in the LDC arm had a 4-year overall survival (OS) of 81.3% vs 83.6% (P = .611), and a 4-year event-free survival (EFS) of 61.5% vs 63.1% (P = .832). In conclusion, the LDC regimen was well tolerated, and was associated with CR, EFS, and OS rates that were not inferior to those of patients treated with the SDC regimen. The trial was registered at www.chictr.org.cn as ChiCTR1800015883.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030972","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:55:54Z","timestamp":1773262554000},"page":"71-83","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Low- vs standard-dose regimens as induction for pediatric AML: a multicenter, randomized noninferiority trial"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-8474","authenticated-orcid":false,"given":"Li","family":"Gao","sequence":"first","affiliation":[{"name":"1Department of Hematology and Oncology, Children\u2019s Hospital of Soochow University, Soochow University, Suzhou, China"},{"name":"2Pediatric Hematology & Oncology Key Laboratory of Higher Education Institutions in Jiangsu Province, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Zhai","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Children\u2019s Hospital of Fudan University, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningling","family":"Wang","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, The Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liao","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifang","family":"Xiao","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Children\u2019s Hospital of Soochow University, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[{"name":"6Department of Pediatrics, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Yang","sequence":"additional","affiliation":[{"name":"7Department of Pediatrics, The Third Xiangya Hospital of Central South University, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueju","family":"Xu","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"An","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Oncology, Xuzhou Children\u2019s Hospital, Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixia","family":"Luo","sequence":"additional","affiliation":[{"name":"10Department of Hematology and Oncology, Kaifeng Children\u2019s Hospital, Kaifeng, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangchun","family":"Yang","sequence":"additional","affiliation":[{"name":"11Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Yuan","sequence":"additional","affiliation":[{"name":"12Department of Pediatric Hematology\/Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyan","family":"He","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhuang","sequence":"additional","affiliation":[{"name":"13Department of Pediatrics, Qilu Hospital of Shandong University, Shandong University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Wang","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Oncology, Children\u2019s Hospital of Fudan University, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3999-0051","authenticated-orcid":false,"given":"Linhai","family":"Yang","sequence":"additional","affiliation":[{"name":"4Department of Pediatrics, The Second Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4156-8332","authenticated-orcid":false,"given":"Weina","family":"Zhang","sequence":"additional","affiliation":[{"name":"14Department of Hematology and Oncology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Liu","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Children\u2019s Hospital of Soochow University, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"He","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Children\u2019s Hospital of Soochow University, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Children\u2019s Hospital of Soochow University, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[{"name":"15Department of Biostatistics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Children\u2019s Hospital of Soochow University, Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[{"name":"14Department of Hematology and Oncology, Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Ju","sequence":"additional","affiliation":[{"name":"13Department of Pediatrics, Qilu Hospital of Shandong University, Shandong University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0086-2626","authenticated-orcid":false,"given":"Qian-Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"16China National Center for Bioinformation, Beijing, China"},{"name":"17Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China"},{"name":"18School of Future Technology, University of Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9956-5647","authenticated-orcid":false,"given":"Raul C.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"19Division of Leukemia\/Lymphoma, Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-6957","authenticated-orcid":false,"given":"Shaoyan","family":"Hu","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, Children\u2019s Hospital of Soochow University, Soochow University, Suzhou, China"},{"name":"2Pediatric Hematology & Oncology Key Laboratory of Higher Education Institutions in Jiangsu Province, Suzhou, China"},{"name":"20Pediatric Hematology & Oncology Center of Jiangsu Province, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2026070211221266900_bib1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/nm.4125","article-title":"Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia","volume":"22","author":"Li","year":"2016","journal-title":"Nat Med"},{"issue":"12","key":"2026070211221266900_bib2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood.2021011694","article-title":"How I treat pediatric acute myeloid leukemia","volume":"138","author":"Rubnitz","year":"2021","journal-title":"Blood"},{"issue":"27","key":"2026070211221266900_bib3","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","article-title":"Collaborative efforts driving progress in pediatric acute myeloid leukemia","volume":"33","author":"Zwaan","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026070211221266900_bib4","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2026070211221266900_bib5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2010.30.6829","article-title":"Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate","volume":"29","author":"Abrahamsson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026070211221266900_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2013-03-491621","article-title":"Results of the AIEOP AML 2002\/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia","volume":"122","author":"Pession","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2026070211221266900_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2013-02-484097","article-title":"Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004","volume":"122","author":"Creutzig","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2026070211221266900_bib8","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1200\/JCO.19.00327","article-title":"Clofarabine can replace anthracyclines and etoposide in remission induction therapy for childhood acute myeloid leukemia: the AML08 multicenter, randomized phase III trial","volume":"37","author":"Rubnitz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026070211221266900_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026070211221266900_bib10","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","article-title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group","volume":"105","author":"Aplenc","year":"2020","journal-title":"Haematologica"},{"issue":"27","key":"2026070211221266900_bib11","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026070211221266900_bib12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/jjco\/hyy061","article-title":"Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Children\u2019s Cancer Group Multi-Center Seamless phase II-III randomized trial (JPLSG AML-12)","volume":"48","author":"Tomizawa","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"16","key":"2026070211221266900_bib13","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.3390\/cancers15164171","article-title":"Risk-stratified therapy for pediatric acute myeloid leukemia","volume":"15","author":"Tomizawa","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026070211221266900_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood.2022018183","article-title":"Treatment intensity in AML: a double-edged sword","volume":"141","author":"Friend","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026070211221266900_bib15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood.2022016487","article-title":"Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study report","volume":"141","author":"Turcotte","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026070211221266900_bib16","first-page":"e1576","article-title":"Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya","volume":"5","author":"van Weelderen","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"6","key":"2026070211221266900_bib17","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00277-019-03661-7","article-title":"Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country","volume":"98","author":"Lins","year":"2019","journal-title":"Ann Hematol"},{"issue":"9","key":"2026070211221266900_bib18","first-page":"2275","article-title":"Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023","volume":"108","author":"Egan","year":"2023","journal-title":"Haematologica"},{"issue":"3","key":"2026070211221266900_bib19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/nsr\/nwz006","article-title":"Ecological principle meets cancer treatment: treating children with acute myeloid leukemia with low-dose chemotherapy","volume":"6","author":"Hu","year":"2019","journal-title":"Natl Sci Rev"},{"key":"2026070211221266900_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-4-46","article-title":"A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"4","author":"Wei","year":"2011","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2026070211221266900_bib21","first-page":"10","article-title":"Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study","volume":"9","author":"Yamada","year":"1995","journal-title":"Leukemia"},{"issue":"10","key":"2026070211221266900_bib22","doi-asserted-by":"crossref","first-page":"e0164238","DOI":"10.1371\/journal.pone.0164238","article-title":"HAG (homoharringtonine, cytarabine, G-CSF) regimen for the treatment of acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis with 2,314 participants","volume":"11","author":"Xie","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"2026070211221266900_bib23","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/bloodadvances.2020003453","article-title":"Minimally myelosuppressive regimen for remission induction in pediatric AML: long-term results of an observational study","volume":"5","author":"Hu","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2026070211221266900_bib24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"7-8","key":"2026070211221266900_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0021-9681(74)90015-0","article-title":"The randomization and stratification of patients to clinical trials","volume":"27","author":"Zelen","year":"1974","journal-title":"J Chronic Dis"},{"issue":"20","key":"2026070211221266900_bib26","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"31","key":"2026070211221266900_bib27","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1200\/JCO.22.02836","article-title":"Homoharringtonine-based induction regimen improved the remission rate and survival rate in Chinese childhood AML: a report from the CCLG-AML 2015 Protocol study","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026070211221266900_bib28","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3390\/cancers15030734","article-title":"Pediatric acute myeloid leukemia post cytotoxic therapy\u2014retrospective analysis of the patients treated in Poland from 2005 to 2022","volume":"15","author":"Czoga\u0142a","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026070211221266900_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/leu.2016.267","article-title":"NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis","volume":"31","author":"Struski","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2026070211221266900_bib30","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1080\/10428194.2022.2047672","article-title":"Adult acute myeloid leukemia patients with NUP98 rearrangement have frequent cryptic translocations and unfavorable outcome","volume":"63","author":"Xie","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026070211221266900_bib31","first-page":"251","article-title":"Adverse prognostic impact of KIT exon 17 mutations despite negative flow cytometric measurable residual disease in pediatric acute myeloid leukemia with RUNX1::RUNX1T1","volume":"110","author":"Kato","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"2026070211221266900_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41467-023-44376-8","article-title":"Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA","volume":"15","author":"Teuber","year":"2024","journal-title":"Nat Commun"},{"issue":"22","key":"2026070211221266900_bib33","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.2024026598","article-title":"Precision medicine for high-risk gene fusions in pediatric AML: a focus on KMT2A, NUP98, and GLIS2 rearrangements","volume":"145","author":"Egan","year":"2025","journal-title":"Blood"},{"issue":"10","key":"2026070211221266900_bib34","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1038\/s41375-024-02368-7","article-title":"Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community","volume":"38","author":"Cuglievan","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"2026070211221266900_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/1\/71\/2531339\/blood_bld-2025-030972-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/1\/71\/2531339\/blood_bld-2025-030972-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:29:21Z","timestamp":1783006161000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/1\/71\/567156\/Low-vs-standard-dose-regimens-as-induction-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030972","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,2]]},"published":{"date-parts":[[2026,7,2]]}}}